title: Serum Fibroblast Growth Factor 1 is Associated with the Decreased Risk of Obesity in Human.
abstract: As a transducer of PPARγ signaling, recent evidence supports that fibroblast growth factor 1 (FGF1) mediates adipose tissue remodeling and insulin sensitivity. This study is to assess the role of serum FGF1 in obesity. A hospital-based case-control study of 154 subjects was conducted. Serum level of FGF1 was measured by enzyme-linked immunosorbent assay. The serum level of FGF1 in the lean (119.0 [103.1-146.1] pg/ml) was higher than it in the subjects with overweight/obesity (111.9 [80.3-127.4] pg/ml, P=0.009). Binary logistic regression models found a reverse association between serum FGF1 level and the risk of overweight/obesity (adjusted odds ratio=0.990, 95% confidence interval [0.981-0.998], P=0.019). Furthermore, serum FGF1 reversely correlated with body mass index (r=-0.176, P=0.029), systolic blood pressure (r=-0.224, P=0.005), diastolic blood pressure (r=-0.185, P=0.022) and triglycerides (r=-0.162, P=0.044). Multiple stepwise linear regression analysis found serum level of FGF1 was dependent on anti-diabetic drugs, hemoglobin A1C, body mass index and sex. Serum level of FGF1 is associated with the decreased risk of obesity in human.
authors.affiliation: School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
authors.forename: Jinzhou
authors.initials: J
authors.lastname: Zhu
authors.affiliation: Department of Geriatrics, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
authors.forename: Yuming
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Cardiology, Zhejiang Hospital, Hangzhou, Zhejiang, China.|The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
authors.forename: Kefu
authors.initials: K
authors.lastname: Zhu
authors.affiliation: School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
authors.forename: Jianguo
authors.initials: J
authors.lastname: Gao
authors.affiliation: School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
authors.forename: Xingyong
authors.initials: X
authors.lastname: Wan
authors.affiliation: Department of Gastroenterology, The Affiliated Hospital, Xuzhou Medical University, Xuzhou, Jiangsu, China.
authors.forename: Xunlei
authors.initials: X
authors.lastname: Pang
authors.affiliation: Department of Gastroenterology, The Affiliated Hospital, Xuzhou Medical University, Xuzhou, Jiangsu, China.
authors.forename: Sujuan
authors.initials: S
authors.lastname: Fei
mesh_terms: D000328:Adult; D000368:Aged; D015992:Body Mass Index; D016022:Case-Control Studies; D005260:Female; D016220:Fibroblast Growth Factor 1 / Q000097:blood*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood* / Q000188:drug therapy; D012307:Risk Factors; D012737:Sex Factors
chemical_list: D016220:Fibroblast Growth Factor 1; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; C517652:hemoglobin A1c protein, human